Nivolumab plus AVD is now FDA-approved for previously untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 years and older.
Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in ...
Myeloma delivery constraints are dominated by CAR T infrastructure and onboarding, while bispecifics are more ...
The country’s experiment with psychedelic medicine has led to positive outcomes, psychiatrists say, but also highlights the ...
Q4 2025 Earnings Call March 24, 2026 8:00 AM EDTCompany ParticipantsMichael Abrams - Chief Financial OfficerJonathan ...
JTF-DC personnel have administered naloxone to more than 100 individuals experiencing drug-related emergencies, the National ...
A new quality improvement initiative demonstrates that evidence-based, clear liquid guidelines can safely reduce fasting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results